This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 5, 2001 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
Pediatric Compounding: Coloring Outside the Lines |
Vol. 5 No. 1 |
6 |
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients |
Vol. 5 No. 1 |
9 |
Flavoring: Compounding a Treat |
Vol. 5 No. 1 |
13 |
Autism in Children |
Vol. 5 No. 1 |
18 |
Methylphenidate in the Treatment of Attention Deficit Disorders |
Vol. 5 No. 1 |
21 |
A Pediatric Miscellany: Excerpts from and Reviews of Current Published Literature |
Vol. 5 No. 1 |
23 |
Book Reviews: Stability and Formulation References |
Vol. 5 No. 1 |
25 |
Glycopyrrolate 1% Cream |
Vol. 5 No. 1 |
28 |
Topical Therapy for Localized Hyperhidrosis |
Vol. 5 No. 1 |
28 |
Methenamine 5% Lotion |
Vol. 5 No. 1 |
29 |
Compounding in History: Pediatric Considerations |
Vol. 5 No. 1 |
30 |
Profile of a Practice |
Vol. 5 No. 1 |
32 |
The Basics of Compounding Powders and Granules |
Vol. 5 No. 1 |
36 |
Electrolyte and Rehydration Powder for Solution-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
Menthol Dusting Powder-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
Cholestyramine 6.5% Ointment |
Vol. 5 No. 1 |
42 |
Ivermectin 0.8% Creme Rinse |
Vol. 5 No. 1 |
43 |
Lidocaine HCl 4%-Epinephrine HCl 0.05%-Tetracaine HCl 0.5% Topical Gel |
Vol. 5 No. 1 |
44 |
Lorazepam 1-mg Chewable Gummy Gels |
Vol. 5 No. 1 |
45 |
Metronidazole Benzoate 400-mg/5-mL Oral Suspension |
Vol. 5 No. 1 |
46 |
Milk of Magnesia Concentrate, Unflavored |
Vol. 5 No. 1 |
47 |
Natural Head Lice Repellant Spray |
Vol. 5 No. 1 |
48 |
Niacinamide 4% Acne Gel |
Vol. 5 No. 1 |
49 |
Poison Ivy Gel with 1% Hydrocortisone |
Vol. 5 No. 1 |
50 |
Promethazine HCl 50-mg/mL in PLO Gel |
Vol. 5 No. 1 |
51 |
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 |
Vol. 5 No. 1 |
52 |
Rhodococcus Equi Pneumonia in Foals |
Vol. 5 No. 1 |
55 |
Sterile-Product Preparations: Mix or Buy? |
Vol. 5 No. 1 |
59 |
Oral Liquid Vehicles, Featured Excipient: |
Vol. 5 No. 1 |
65 |
Purchasing Chemicals for Pharmaceutical Compounding |
Vol. 5 No. 1 |
67 |
Compatibility Screening of Hextend During Simulated Y-Site Administration with Other Drugs |
Vol. 5 No. 1 |
69 |
Stability of Ethacrynate Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 5 No. 1 |
73 |
Stability of Acyclovir Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 5 No. 1 |
75 |
Calculations |
Vol. 5 No. 1 |
78 |
The Use of Psychoactive Agents in Veterinary Medicine |
Vol. 5 No. 2 |
86 |
Benzoate or Not to Benzoate: Cats Are the Question, To |
Vol. 5 No. 2 |
89 |
Feline Ophthalmic Disease: Feline Herpesvirus and Systemic Hypertension |
Vol. 5 No. 2 |
92 |
Evaluating Transdermal Medication Forms for Veterinary Patients, Part 1 |
Vol. 5 No. 2 |
95 |
Regulatory Issues for the Use of Bulk Drugs in Veterinary Compounding |
Vol. 5 No. 2 |
97 |
Drugs Banned for Use in Food Animals: An Explanation |
Vol. 5 No. 2 |
101 |
A Simplified Guide to Veterinary Compounding |
Vol. 5 No. 2 |
104 |
Equipment for Large-Volume Aseptic Veterinary Compounding |
Vol. 5 No. 2 |
106 |
Compounded Injectables for Veterinary Use |
Vol. 5 No. 2 |
107 |
Book Reviews: Veterinary Compounding |
Vol. 5 No. 2 |
108 |
From Wagon-Era Paregoric to Computer-Era Herbals |
Vol. 5 No. 2 |
112 |
Wish You Were Here: The Niagara Apothecary |
Vol. 5 No. 2 |
116 |
Profile of a Practice: Custom Rx Compounding and Natural Pharmacy |
Vol. 5 No. 2 |
118 |
The Basics of Compounding Emulsions, Part 1 |
Vol. 5 No. 2 |
120 |
Diazoxide 50-mg/mL Suspension, Veterinary |
Vol. 5 No. 2 |
126 |
Dimethyl Sulfoxide 50% Cream, Veterinary |
Vol. 5 No. 2 |
127 |
EDTA-TRIS Otic Solution V-2 (Veterinary) |
Vol. 5 No. 2 |
128 |
Flea Bite Gel |
Vol. 5 No. 2 |
129 |
Gentamicin, Polymyxin, Neomycin, and Hydrocortisone Otic Drops |
Vol. 5 No. 2 |
130 |
Iodine 2% in Oil Injection |
Vol. 5 No. 2 |
131 |
Methimazole 5-mg/0.1-mL in Pluronic Lecithin Organogel |
Vol. 5 No. 2 |
132 |
Sucrose Octaacetate and Capsicum Spray for Pets |
Vol. 5 No. 2 |
133 |
Veterinary Antiseptic Emollient |
Vol. 5 No. 2 |
134 |
Veterinary Oral Pastes |
Vol. 5 No. 2 |
135 |
Infertility Care and the Role of the Compounding Pharmacist |
Vol. 5 No. 2 |
136 |
Consolidation of Pharmacy Compounding Services: An Alternative to Outsourcing |
Vol. 5 No. 2 |
140 |
Ointment Vehicles, Featured Excipient: |
Vol. 5 No. 2 |
145 |
Standard Operating Procedure: Certificates of Analysis of Materials Used for Pharmaceutical Compounding |
Vol. 5 No. 2 |
147 |
Chemical Stability of Methylprednisolone Sodium Succinate After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes |
Vol. 5 No. 2 |
148 |
Stability of Cefepime Hydrochloride After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 5 No. 2 |
151 |
Stability and Dissolution of Lozenge and Emulsion Formulations of Metronidazole Benzoate |
Vol. 5 No. 2 |
153 |
Calculations |
Vol. 5 No. 2 |
157 |
PostScription: Case Reports and Formulations, George Roentsch, RPh. |
Vol. 5 No. 2 |
160 |
Piracetam 100-mg, Ergoloid Mesylates 6-mg, and Selegiline 2.5-mg/0.2-mL Gel ("Brain Gel") |
Vol. 5 No. 2 |
160 |
Oxytetracycline 15-mg/0.1-mL TD Cream |
Vol. 5 No. 2 |
160 |
Motivation and Management: How to Build Your Business into the Job You Love |
Vol. 5 No. 3 |
166 |
A New Trend in Pharmacy Practice: Private Consultations |
Vol. 5 No. 3 |
170 |
Formulations for Success in Compounding, Part 1 |
Vol. 5 No. 3 |
174 |
Developing a Business Plan for a Compounding Specialty Pharmacy |
Vol. 5 No. 3 |
176 |
Pricing Strategies |
Vol. 5 No. 3 |
180 |
The Pharmacist Manpower Shortage: How to Recruit and Retain Key Employees |
Vol. 5 No. 3 |
182 |
Book Reviews: Business Topics for Compounding Pharmacists |
Vol. 5 No. 3 |
185 |
Software for the Compounding Pharmacist: A Review |
Vol. 5 No. 3 |
187 |
Capsule-Weighing and Trituration Calculations |
Vol. 5 No. 3 |
192 |
Irrigation with Piperacillin for the Treatment of Bladder Infection: A Case Study |
Vol. 5 No. 3 |
195 |
Compounding in History: Compounding Economics |
Vol. 5 No. 3 |
196 |
Stoughton's Bitters |
Vol. 5 No. 3 |
197 |
Tinctura Kino Composita |
Vol. 5 No. 3 |
197 |
The Basics of Compounding Emulsions, Part 2 |
Vol. 5 No. 3 |
198 |
Dry Skin and Massage Lotion-Example |
Vol. 5 No. 3 |
201 |
Amphotericin 5-mg/mL Nasal Inhalation |
Vol. 5 No. 3 |
204 |
Anthralin 1% in Lipid Crystals Cream |
Vol. 5 No. 3 |
205 |
Bifonazol 1% and Urea 40% in White Petrolatum |
Vol. 5 No. 3 |
206 |
Hand Cream, Protective |
Vol. 5 No. 3 |
207 |
Idoxuridine 15% in Dimethyl Sulfoxide (DMSO) |
Vol. 5 No. 3 |
208 |
Mitomycin 0.02% Ophthalmic Solution |
Vol. 5 No. 3 |
209 |
Phenytoin 100- to 400-mg Rectal Suppositories |
Vol. 5 No. 3 |
210 |
Tacrolimus 0.3% Ointment |
Vol. 5 No. 3 |
211 |
Tetracycline HCl 1% Ophthalmic Ointment |
Vol. 5 No. 3 |
212 |
Tobramycin Sulfate 0.3% and Diclofenac Sodium 0.1% Ophthalmic Solution |
Vol. 5 No. 3 |
213 |
Evaluating Transdermals Medication Froms for Veterinary Patients, Part 2 |
Vol. 5 No. 3 |
214 |
The American Veterinary Medical Association Compounding Position Statement |
Vol. 5 No. 3 |
216 |
Natural Progesterone in Natural Hormone Replacement Therapy, The Role of |
Vol. 5 No. 3 |
218 |
Pharmacy Cleanroom Project Management Considerations: An Experience-Based Perspective |
Vol. 5 No. 3 |
221 |
Establishing and Maintaining a Compounding Pharmacy Reference Library |
Vol. 5 No. 3 |
226 |
Official Water-Repelling Agents: The Official Silicones, Featured Excipient: |
Vol. 5 No. 3 |
228 |
Calculations |
Vol. 5 No. 3 |
229 |
Stability of Piperacillin Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 5 No. 3 |
230 |
Stability of Oral Liquid Dosage Forms of Ethacrynic Acid |
Vol. 5 No. 3 |
232 |
Preparation and Evaluation of Sustained Drug Release from Pluronic Polyol Rectal Suppositories |
Vol. 5 No. 3 |
234 |
PostScription: Compounding Pharmacists |
Vol. 5 No. 3 |
240 |
Quality Assurance for Sterile Products |
Vol. 5 No. 4 |
246 |
Sterile Compounding with Barrier-Isolation Technology |
Vol. 5 No. 4 |
254 |
Bacterial Endotoxins and Pyrogens |
Vol. 5 No. 4 |
259 |
Evolution of the United States Pharmacopeia Chapter <1206>: "Sterile Preparations - Pharmacy Practices" |
Vol. 5 No. 4 |
265 |
Antineoplastic Agents |
Vol. 5 No. 4 |
268 |
Compounding Issues and Accreditation Agencies |
Vol. 5 No. 4 |
273 |
Book Reviews |
Vol. 5 No. 4 |
275 |
Sterile Compounding: Excerpts from the Reviews of Current Published Literature |
Vol. 5 No. 4 |
278 |
Evaluating Transdermal Medication Forms for Veterinary Patients, Part 3: Methimazole |
Vol. 5 No. 4 |
282 |
Analytical Testing Facilities and Products |
Vol. 5 No. 4 |
284 |
Formulations for Success, Part 2 |
Vol. 5 No. 4 |
287 |
Wish You Were Here: The Stabler-Leadbeater Apothecary Museum |
Vol. 5 No. 4 |
290 |
Basics of Compounding: Suspensions |
Vol. 5 No. 4 |
294 |
Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Sugar-Free Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Spironolactone Oral Suspension 2-mg/mL |
Vol. 5 No. 4 |
297 |
Progesterone Oral Suspension 40-mg/mL |
Vol. 5 No. 4 |
297 |
Progesterone Enema 200-mg/mL |
Vol. 5 No. 4 |
297 |
Xanthan Gum Oral Suspension Vehicle 0.3% |
Vol. 5 No. 4 |
297 |
Wound Care Mixture |
Vol. 5 No. 4 |
297 |
Cefazolin Ophthalmic Solution, USP 0.35- mg/mL |
Vol. 5 No. 4 |
300 |
Cyclopentolate HCl 0.5%, Phenylephrine HCl 2.5%, and Tropicamide 0.5% Ophthalmic Solution |
Vol. 5 No. 4 |
301 |
Fibrin Glue |
Vol. 5 No. 4 |
302 |
Hyaluronidase Injection |
Vol. 5 No. 4 |
303 |
Hypertonic Sodium Chloride 20% Sclerotherapy Injections |
Vol. 5 No. 4 |
304 |
Metronidazole and Neomycin Sulfate Irrigation Solution |
Vol. 5 No. 4 |
305 |
Pediatric Preoperative Cocktail Injection |
Vol. 5 No. 4 |
306 |
Phenylephrine 0.25% Ophthalmic Solution, Preservative Free |
Vol. 5 No. 4 |
307 |
Sclerotherapy Injections of Phenol for Pain Management |
Vol. 5 No. 4 |
308 |
Tissue Plasminogen Activator (TPA) 25-mcg/100-mcL Ophthalmic Solution |
Vol. 5 No. 4 |
309 |
Wetting and/or Solubilizing Agents, Featured Excipient: |
Vol. 5 No. 4 |
310 |
Maintenance of the Cleanroom |
Vol. 5 No. 4 |
313 |
Incompatibilities of Lansoprazole Injection with Other Drugs During Simulated Y-Site Coadministration |
Vol. 5 No. 4 |
314 |
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes |
Vol. 5 No. 4 |
320 |
Compatibility and Stability of Potassium Chloride and Magnesium Sulfate in 0.9% Sodium Chloride Injection and 5% Dextrose Injection Solutions |
Vol. 5 No. 4 |
323 |
Calculations |
Vol. 5 No. 4 |
325 |
PostScription: pH Values of Nafcillin Sodium in 0.9% Sodium Chloride Injection After the Addition of Sodium Bicarbonate Injection To Prevent Phlebitis - A Letter to the Editor |
Vol. 5 No. 4 |
328 |
Natural Hormone Replacement Therapy: What It Is and What Consumers Really Want |
Vol. 5 No. 5 |
332 |
Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment |
Vol. 5 No. 5 |
336 |
Bioidentical Hormones in the Treatment of Osteoporosis |
Vol. 5 No. 5 |
339 |
The Value of Hormone Assessment |
Vol. 5 No. 5 |
342 |
Estrogen Replacement: A Review of Current Literature |
Vol. 5 No. 5 |
346 |
Treating Andropause: Prohormones and Hormone Metabolic Modifiers |
Vol. 5 No. 5 |
351 |
Bioidentical Topical Progesterone: A Survey of Patients |
Vol. 5 No. 5 |
354 |
Book Reviews: Hormone Replacement Therapy |
Vol. 5 No. 5 |
356 |
Charting Systems: Organizing Information Effectively |
Vol. 5 No. 5 |
360 |
Minimizing the Risk of Cholesterol-Lowering Therapy |
Vol. 5 No. 5 |
362 |
Compounding in History: Treatment at the Change of Life |
Vol. 5 No. 5 |
365 |
Flush Powder, No. 2 |
Vol. 5 No. 5 |
366 |
Tincture of Black Cohosh |
Vol. 5 No. 5 |
366 |
Lydia Pinkham's Vegetable Compound |
Vol. 5 No. 5 |
366 |
The Basics of Compounding: Tablets and Pills |
Vol. 5 No. 5 |
369 |
Estriol 2-mg/mL and Estradiol 0.5-mg/mL in Pluronic Lecithin Organogel (PLO) |
Vol. 5 No. 5 |
374 |
Estriol 2-mg/g with Estradiol 0.5-mg/g Vaginal Cream |
Vol. 5 No. 5 |
375 |
Libido Cream |
Vol. 5 No. 5 |
376 |
Progesterone 50-mg/mL Clear Topical Solution |
Vol. 5 No. 5 |
377 |
Progesterone Low-Potency 0.0065% Topical Cream |
Vol. 5 No. 5 |
378 |
Sildenafil 1% Topical Cream |
Vol. 5 No. 5 |
379 |
Testosterone 1-mg/0.1-mL Pluronic Lecithin Organogel (PLO) |
Vol. 5 No. 5 |
380 |
Testosterone 2-mg and Dehydroepiandrosterone (DHEA) 15-mg Troches |
Vol. 5 No. 5 |
381 |
Testosterone 25-mg/mL Clear Solution |
Vol. 5 No. 5 |
382 |
Testosterone 2% Scalp Lotion |
Vol. 5 No. 5 |
383 |
Compounding Containment Devices: Buyer Be Aware |
Vol. 5 No. 5 |
384 |
Capsule and Tablet Disintegrating Agents, Featured Excipient: |
Vol. 5 No. 5 |
389 |
Calculations |
Vol. 5 No. 5 |
391 |
Developing a Capsule Formulation |
Vol. 5 No. 5 |
392 |
Stability of Ephedrine Sulfate at Ambient Temperature and 4°C in Polypropylene Syringes |
Vol. 5 No. 5 |
394 |
Assessment of the Stability of Teicoplanin in Intravenous Infusions |
Vol. 5 No. 5 |
397 |
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release |
Vol. 5 No. 5 |
401 |
PostScription: Compounding Errors: Lessons Learned, Never To Be Forgotten |
Vol. 5 No. 5 |
408 |
High-tech Compounding: State-of-the-art Equipment Improves Products and Profit |
Vol. 5 No. 6 |
412 |
High-tech Rx Compliance |
Vol. 5 No. 6 |
419 |
High-tech Marketing Techniques |
Vol. 5 No. 6 |
420 |
Barrier Isolators: A New, High-tech Option for the Preparation of Sterile Admixtures |
Vol. 5 No. 6 |
422 |
Nanotechnology: The Ultimate Alchemy |
Vol. 5 No. 6 |
424 |
Future Trends in High-technology Pharmacy Compounding |
Vol. 5 No. 6 |
426 |
Using Technology to Enhance the Practice of Pharmacy |
Vol. 5 No. 6 |
427 |
Tips for Preventing Viruses… |
Vol. 5 No. 6 |
430 |
Topical Secretin for the Treatment of Autism |
Vol. 5 No. 6 |
436 |
Wish You Were Here: Vienna, Austria |
Vol. 5 No. 6 |
438 |
Basics of Compounding: Parenteral Preparations |
Vol. 5 No. 6 |
441 |
Acetic Acid 5% Iontophoresis Solution |
Vol. 5 No. 6 |
450 |
Ceftazidime 20-mg/mL for Ambulatory Infusion Pump |
Vol. 5 No. 6 |
451 |
Dexamethasone, Lidocaine, and Verapamil Iontophoresis Solutions for Peyronie's Disease |
Vol. 5 No. 6 |
452 |
Doxycycline Hyclate 200-mg/mL Avian Injection |
Vol. 5 No. 6 |
453 |
Hydrocortisone 10% Phonophoresis Gel |
Vol. 5 No. 6 |
454 |
Sufentanil 25-mcg/mL, Bupivacaine 1-mg/mL Intrathecal Solution |
Vol. 5 No. 6 |
455 |
Tissue Plasminogen Activator (TPA) 0.5-mg/mL, 1.0-mg/mL, or 2.0-mg/mL for Catheter Occlusion |
Vol. 5 No. 6 |
456 |
Tobramycin-impregnated Polymethylmethacrylate Beads |
Vol. 5 No. 6 |
457 |
Total Parenteral Nutrition Solution |
Vol. 5 No. 6 |
458 |
Vancomycin 5-mg Sponge Disks |
Vol. 5 No. 6 |
459 |
Hormone Replacement Therapy, Part 2: Estrogen Defined |
Vol. 5 No. 6 |
460 |
The Science Behind Hormone Replacement Therapy, Part 1 |
Vol. 5 No. 6 |
462 |
New Perspectives on Vancomycin Use in Home Care, Part 1 |
Vol. 5 No. 6 |
465 |
Tablet and Lozenge Binders, Featured Excipient: |
Vol. 5 No. 6 |
471 |
Training Personnel |
Vol. 5 No. 6 |
474 |
Cross-contamination in Porcelain Mortars |
Vol. 5 No. 6 |
476 |
Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets |
Vol. 5 No. 6 |
480 |
Stability of Pentobarbital Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Repackaging in Glass and Polypropylene Syringes |
Vol. 5 No. 6 |
482 |
Calculations |
Vol. 5 No. 6 |
485 |
PostScription: Lifelong Learning + Technology = Valuable Tools for the Compounding Pharmacist |
Vol. 5 No. 6 |
488 |